AxoGen, Inc. (0HKD.L)

6.44 -0.14 (-2.10%) At close: 05:19PM BST

AxoGen, Inc.

13631 Progress Boulevard
Suite 400
Alachua, FL 32615
United States
386 462 6800
https://www.axogeninc.com

Sector(s): 
Industry: 
Full-time employees: 426

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Karen Zaderej	Chairman, President & CEO	852.18k	150.31k	1962
Mr. Michael Donovan	Vice President of Operations	406.02k	30.75k	1965
Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.	Chief Financial Officer	N/A	N/A	1975
Mr. Harold D. Tamayo	Vice President of Finance & Investor Relations	N/A	N/A	N/A
Mr. Marc A. Began	Executive VP, General Counsel & Chief Compliance Officer	N/A	N/A	1968
Ms. Doris Quackenbush	Vice President of Sales	N/A	N/A	N/A
Mr. Jens Schroeder Kemp	Chief Marketing Officer	N/A	N/A	N/A
Mr. Erick DeVinney	Chief Innovation Officer	N/A	N/A	1976
Dr. Ivica Ducic M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Corporate governance

AxoGen, Inc.’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.